CAR T-Cell therapies in lymphoma: current landscape, ongoing investigations, and future directions  

作　　者：J.Erika Haydu Jeremy S.Abramson 

机构地区：[1]Center for Lymphoma,Massachusetts General Hospital&Harvard Medical School,Boston,MA 02114,USA.

出　　处：《Journal of Cancer Metastasis and Treatment》2021年第1期497-510,共14页癌症转移与治疗（英文版）

摘　　要：Chimeric antigen receptor(CAR)T-cell therapy has significantly improved outcomes for patients with relapsed/refractory large B-cell lymphoma,mantle cell lymphoma,and follicular lymphoma,with multiple FDA-approved CAR T products now commercially available.Ongoing studies seek to move CAR T-cells to earlier lines of therapy and to characterize the efficacy and safety of CAR T-cell approaches in additional lymphoma histologies including relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia.Other areas of active research address CAR T in combination with other lymphoma-directed therapies,and mechanisms of CAR T resistance.This review focuses on the FDA-approved anti-CD19 CAR T products for B-cell lymphomas,management of CAR T-cell-associated toxicities,approaches to bridging therapy,and ongoing clinical trials and future research directions across a broad range of lymphoma histologies.

关 键 词：CAR T-cells cell therapy adoptive immunotherapy non-Hodgkin lymphoma aggressive lymphoma indolent lymphoma mantle cell lymphoma diffuse large B-cell lymphoma 

分 类 号：R73[医药卫生—肿瘤]